Table 3 Selected characteristics of study participants at the time of NADC diagnosis
Lung cancer | Hodgkin’s lymphoma | Anal cancer | Any NADC | ||
|---|---|---|---|---|---|
Total number | 140 (100.0) | 112 (100.0) | 79 (100.0) | 880 (100.0) | |
Gender, n (%) | Male | 120 (85.7) | 95 (84.8) | 69 (87.3) | 708 (80.5) |
Female | 20 (14.3) | 17 (15.2) | 10 (12.7) | 173 (19.5) | |
Age (years) | Median (IQR) | 54 (47, 59) | 43 (38, 50) | 48 (44, 51) | 50 (44, 59) |
Mode of HIV acquisition, n (%) | Men having sex with men | 63 (45.0) | 61 (54.5) | 52 (65.8) | 408 (46.4) |
Injection drug user | 25 (17.9) | 15 (13.4) | 15 (19.0) | 153 (17.4) | |
Heterosexual | 39 (27.9) | 29 (25.9) | 7 (8.9) | 256 (29.1) | |
Other/unknown | 13 (9.3) | 7 (6.3) | 5 (6.3) | 63 (7.2) | |
Ethnic group, n (%) | White | 72 (51.4) | 70 (62.5) | 46 (58.2) | 479 (54.4) |
Black | 1 (0.7) | 4 (3.6) | 1 (1.3) | 27 (3.1) | |
Other | 0 (-) | 6 (5.4) | 0 (-) | 11 (1.3) | |
Unknown/not collected | 67 (47.9) | 32 (28.6) | 32 (40.5) | 363 (41.3) | |
BMI (kg/m2), n (%) | <18 | 10 (7.1) | 3 (2.7) | 3 (3.8) | 46 (5.2) |
≥18, ≤26 | 64 (45.7) | 69 (61.6) | 48 (60.8) | 439 (49.9) | |
>26, ≤30 | 9 (6.4) | 17 (15.2) | 5 (6.3) | 79 (9.0) | |
>30 | 6 (4.3) | 5 (4.5) | 3 (3.8) | 43 (4.9) | |
Unknown | 51 (36.4) | 25 (22.3) | 20 (25.3) | 273 (31.0) | |
CD4 count (cells/mm3) | Median (IQR) | 365 (230, 487) | 274 (167, 451) | 380 (253, 580) | 392 (245, 580) |
Nadir CD4 count (cells/m3) | Median (IQR) | 108 (53, 212) | 134 (49, 232) | 50 (16, 20) | 127 (49, 245) |
HIV RNA (log10 copies/ml) | Median (IQR) | 1.7 (1.7, 2.3) | 1.7 (1.7, 3.8) | 1.7 (1.7, 2.0) | 1.7 (1.7, 2.4) |
Prior NADC, n (%) | 8 (5.7) | 4 (3.6) | 4 (5.1) | 48 (5.5) | |
Prior ADC, n (%) | 9 (6.4) | 11 (9.9) | 15 (19.0) | 91 (10.3) | |
Year of diagnosis, n (%) | 2004-2005 | 46 (32.9) | 31 (27.7) | 20 (25.3) | 238 (27.0) |
2006-2007 | 45 (32.1) | 54 (48.2) | 33 (41.7) | 339 (38.5) | |
2008-2010 | 49 (35.0) | 27 (24.1) | 26 (32.9) | 303 (34.4) | |
Smoking status, n (%) | Current Smoker | 71 (50.7) | 45 (40.2) | 40 (50.6) | 386 (43.9) |
Ex-smoker | 55 (39.3) | 30 (26.8) | 22 (27.9) | 253 (28.8) | |
Never smoked | 3 (2.1) | 21 (18.8) | 9 (11.4) | 136 (15.5) | |
Unknown | 11 (7.9) | 16 (14.3) | 8 (10.1) | 105 (11.9) | |
HCV positive, n (%) | 11 (7.9) | 5 (4.5) | 8 (10.1) | 75 (8.5) | |
HBV positive, n (%) | 5 (3.6) | 6 (5.4) | 6 (7.6) | 55 (6.3) | |
Any use of ARV, n (%) | 130 (92.9) | 99 (88.4) | 78 (98.7) | 813 (92.4) | |
Stage of disease, n (%) | N | 76 | 36 | 51 | Not Collected |
Localised | 18 (23.7) | 6 (16.7) | 31 (60.8) | ||
Disseminated | 58 (76.3) | 30 (83.3) | 20 (39.2) | ||